PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-1.08
Both companies show negative D/E. Martin Whitman would investigate if industry distress creates special situation opportunities.
-6.56
Net cash position while CRVO shows net debt of 0.00. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.
-32.85
Negative coverage while CRVO shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
1.75
Current ratio exceeding 1.5x CRVO's 0.03. Charlie Munger would verify if this advantage translates to better supplier terms.
No Data
No Data available this quarter, please select a different quarter.